DelveInsight’s, “Rheumatoid Arthritis (RA) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Rheumatoid Arthritis (RA): Overview
Rheumatoid arthritis (RA) is a chronic, progressive, and disabling autoimmune disease. Rheumatoid Arthritis (RA) mainly attacks the joints, usually many joints at once. RA commonly affects joints in the hands, wrists, and knees. Signs and symptoms of RA include pain or aching in more than one joint, stiffness in more than one joint, tenderness and swelling in more than one joint, weight loss, weakness, fever, and/or fatigue or tiredness. Rheumatoid Arthritis (RA) is diagnosed by reviewing symptoms, conducting a physical examination, and doing X-rays and lab tests. Treatment for Rheumatoid Arthritis (RA) usually includes the use of medications that slow disease and prevent joint deformity, called disease-modifying antirheumatic drugs (DMARDs); biological response modifiers (biologicals) are medications that are an effective second-line treatment.
"Rheumatoid Arthritis (RA) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rheumatoid Arthritis (RA) pipeline landscape is provided which includes the disease overview and Rheumatoid Arthritis (RA) treatment guidelines. The assessment part of the report embraces, in depth Rheumatoid Arthritis (RA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rheumatoid Arthritis (RA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Rheumatoid Arthritis (RA) R&D. The therapies under development are focused on novel approaches to treat/improve Rheumatoid Arthritis (RA).
This segment of the Rheumatoid Arthritis (RA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rheumatoid Arthritis (RA) Emerging Drugs
Ozoralizumab: Taisho Pharmaceutical
Ozoralizumab (ATN-103) is a trivalent humanized low molecular weight compound that combines two anti-TNFα NANOBODY® VHHs and one anti-serum albumin NANOBODY® VHH. Ozoralizumab is about a quarter of the size of conventional IgG antibodies. Ozoralizumab binds to two subunits of TNFα and potently neutralizes its action. Ozoralizumab, initially discovered by Ablynx. In March 2021, Taisho announced that it submitted an application for approval to manufacture and market the anti-TNFα NANOBODY® therapeutic (generic name: ozoralizumab) to the Ministry of Health, Labour and Welfare for rheumatoid arthritis (RA).
ABX464: Abivax
ABX464 is an oral, first-in-class, small molecule that binds to the RNA cap binding protein (CBC 80/20) complex which sits at the 5' end of every RNA molecule and enhances pre-mRNA splicing. The drug is in Phase II clinical studies for the treatment of Rheumatoid Arthritis (RA).
Further product details are provided in the report……..
This segment of the report provides insights about the different Rheumatoid Arthritis (RA) drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 100+ key companies which are developing the therapies for Rheumatoid Arthritis (RA). The companies which have their Rheumatoid Arthritis (RA) drug candidates in the most advanced stage, i.e. Preregistration include, Taisho Pharmaceutical.
DelveInsight’s report covers around 100+ products under different phases of clinical development like
Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rheumatoid Arthritis (RA) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rheumatoid Arthritis (RA) drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Rheumatoid Arthritis (RA): Overview
Pipeline Therapeutics
Therapeutic Assessment
Rheumatoid Arthritis (RA) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
SHR 0302: Jiangsu Hengrui Medicine Co.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ABX464: Abivax
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Amilo-5MER: Galmed Pharmaceuticals
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
KT 474: Kymera Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Appendix
List of Table
Table 1: Total Products for Rheumatoid Arthritis (RA)
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Rheumatoid Arthritis (RA)
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Abivax
• Kymera Therapeutics
• Akari Therapeutics
• Sierra Oncology
• Neutrolis Therapeutics
• Centivax
• Taisho
• Hope Biosciences
• UCB
• Galmed Pharmaceuticals
• Celon Pharma
• Jiangsu Hengrui Medicine Co.
• Cyxone
• Oryn Therapeutics
